drugset / Trial / NCT00663884

Glufast On Insulin Glargine Trial in Type 2 DM

NCT00663884

Phase 4 Completed 167 enrolled JW Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

We will evaluate the efficacy and safety of combination therapy of 10 mg mitiglinide or 0.2mg voglibose with insulin glargine for 16 weeks after single administration of insulin glargine for 4 weeks in type 2 diabetic patients whose glycemic control were not enough despite administration of oral antidiabetic drug or insulin glargine.

Timeline

Start
2008-02
Primary completion
2009-07
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitiglinide Small molecule 10 mg
Comparator Voglibose Small molecule 0.2 mg